These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22284785)

  • 1. The scope and potentials of functional radionuclide imaging towards advancing personalized medicine in oncology: emphasis on PET-CT.
    Basu S
    Discov Med; 2012 Jan; 13(68):65-73. PubMed ID: 22284785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.
    Basu S; Alavi A
    PET Clin; 2016 Jul; 11(3):203-7. PubMed ID: 27321025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?
    Basu B; Basu S
    Cancer Biother Radiopharm; 2016 Apr; 31(3):75-84. PubMed ID: 27093341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer.
    Mac Manus MP; Hicks RJ
    Semin Nucl Med; 2012 Sep; 42(5):308-19. PubMed ID: 22840596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
    Chavdarova LI; Tzonevska AD; Piperkova EN
    Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions.
    Delbeke D; Schöder H; Martin WH; Wahl RL
    Semin Nucl Med; 2009 Sep; 39(5):308-40. PubMed ID: 19646557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome.
    Dimitrakopoulou-Strauss A
    Future Oncol; 2015; 11(7):1083-91. PubMed ID: 25804123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Fanti S
    PET Clin; 2015 Oct; 10(4):487-94. PubMed ID: 26384595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a role for PET-CT and SPECT-CT in pediatric oncology?
    Biermann M; Schwarzlmüller T; Fasmer KE; Reitan BC; Johnsen B; Rosendahl K
    Acta Radiol; 2013 Nov; 54(9):1037-45. PubMed ID: 23319723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From PET/CT to PET/MRI: advances in instrumentation and clinical applications.
    Hu Z; Yang W; Liu H; Wang K; Bao C; Song T; Wang J; Tian J
    Mol Pharm; 2014 Nov; 11(11):3798-809. PubMed ID: 25058336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hybrid imaging: clinical evidence, opportunities].
    Trencsényi G; Barna SK; Garai I
    Orv Hetil; 2015 Dec; 156(52):2110-5. PubMed ID: 26686747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies.
    Pattison DA; Hofman MS
    PET Clin; 2015 Oct; 10(4):461-76. PubMed ID: 26384593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and anatomical imaging in pediatric oncology: which is best for which tumors.
    Voss SD
    Pediatr Radiol; 2019 Oct; 49(11):1534-1544. PubMed ID: 31620853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging.
    Bockisch A; Freudenberg LS; Schmidt D; Kuwert T
    Semin Nucl Med; 2009 Jul; 39(4):276-89. PubMed ID: 19497404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET and PET/CT.
    Krause BJ; Schwarzenböck S; Souvatzoglou M
    Recent Results Cancer Res; 2013; 187():351-69. PubMed ID: 23179888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there still a role for SPECT-CT in oncology in the PET-CT era?
    Hicks RJ; Hofman MS
    Nat Rev Clin Oncol; 2012 Dec; 9(12):712-20. PubMed ID: 23149896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis.
    Sebro R; Mari-Aparici C; Hernandez-Pampaloni M
    Acta Radiol; 2013 Jun; 54(5):534-9. PubMed ID: 23463863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
    Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
    J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.